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Abstract Gallbladder carcinoma (GBC) is the most common
cancer of the biliary tract. Lymph node metastasis (LNM) is
the major diffusion route of GBC and is a prognosis factor.
The aim of study was to assess the potential of the serum
VEGF-C and VEGF-D (sVEGF-C/D) levels to predict the
presence of LNM and the survival of GBC patients. The pre-
operative sVEGF-C/D levels of 31 patients with GBC, 10
patients with cholesterol polyps, and 10 healthy volunteers
were measured by enzyme-linked immunoadsorbent assay
(ELISA). The sVEGF-C/D levels of patients with GBC were
significantly higher than those of people with healthy gall-
bladders (p<0.001 and p=0.001, respectively) and cholesterol
polyp (p=0.032 and p=0.004, respectively). In GBC, the
sVEGF-C levels were associated with LNM (p=0.011), dis-
tant metastasis (p=0.018), and stage (p=0.045), but the
sVEGF-D levels had a significant association with the tumor
depth (p=0.001), LNM (p=0.001), distant metastasis (p=
0.047), and stage (p=0.002). The sVEGF-C/D diagnostic
values for the presence of GBC were sensitivity of 71.0 and
74.2 % and specificity of 80.0 and 85.0 %, respectively. With
respect to the diagnosis of LNM, the diagnostic values of
sVEGF-C/D were as follows: sensitivity 81.2 and 87.5 %
and specificity 73.3 and 80.0 %, respectively. The mean sur-
vival time with high sVEGF-C was significantly shorter than
that with low sVEGF-C (p<0.001), which was also true for
low sVEGF-D (p=0.032). The preoperative sVEGF-C/D
levels might be reliable biomarkers for the presence of disease
and LNM in patients with GBC. The sVEGF-C/D levels may
be prognosis factors that can predict a poor outcome for GBC
patients.
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Introduction
Gallbladder carcinoma (GBC) is the sixth most common can-
cer of the gastrointestinal tract and is most common cancer of
the biliary tract [1]. According to epidemiological investiga-
tions, the incidence rates are extraordinarily high in Asia and
relatively high in Korea (13.7/100,000). The 5-year survival
rate is only 5%, and the overall mean survival time is 6months
[2]. Radical resection is the most effective and only potentially
curative treatment [3, 4]. However, because there are few ef-
fective diagnostic measures and classical symptoms, most of
patients with GBC are treated at late stages of the disease,
resulting in a poor overall prognosis [5]. Lymph node metas-
tasis (LNM) is the major diffusion route of GBC. It is not only
an important component of tumor staging but also a prognos-
tic factor for GBC. Moreover, LNM often occurs in the early
stage of GBC. Therefore, it is particularly important to
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identify a method that can exactly assess the LNM of GBC
before an operation.
Vascular endothelial growth factors C and D (VEGF-C/D)
have been identified as the important numbers of VEGF fam-
ily and are considered as the lymphangiogenic factors. VEGF-
C/D induce the formation of lymphatic ducts and promote
lymph node metastasis in combination with VEGFR-3 [6].
Many recent studies have observed tumor VEGF-C/D over-
expression in many carcinomas, specifically those whose ma-
jor diffusion route is LNM, such as gastric carcinoma [7] and
colorectal cancer [8]. The studies have shown that tumor
VEGF-C/D overexpression is correlated with the presence of
carcinoma and LNM and may be related to the prognosis.
Moreover, our group [9] has found that VEGF-C/D are in-
volved in the lymphangiogenesis in GBC and induce LNM
of the tumor. VEGF-C/D might be useful for evaluating LNM
and the prognosis in GBC.
Recently, studies on the serum VEGF-C/D (sVEGF-C/D)
levels have become popular. Wang et al. [10] reported that the
serum VEGF-C level is related to LNM and the poor progno-
sis of patients with gastric cancer, which has a positive corre-
lation with the tumor VEGF-C expression. Lai et al. [11] dem-
onstrated that the serum VEGF-D level correlates with the
presence of cervical lymph node metastases and might be a
useful prognostic indicator in papillary thyroid carcinoma pa-
tients. Therefore, we posit that the serum VEGF-C/D levels
correlate with the tumor expression of VEGF-C/D and may be
used as tumor makers and prognostic factors for GBC
patients.
To date, few studies have demonstrated whether the serum
VEGF-C/D levels predict the presence of LNM and indicate
the survival of GBC patients. Few effective biomarkers from
the serum of patients with GBC have been used in the clinic,
particularly as diagnosis tools for LNM. The aim of the study
was to evaluate the potential for the serum VEGF-C/D levels




Between November 2008 and February 2014, serum samples
were collected from 31 patients with histopathologically prov-
en GBC who were treated with surgery but not preoperative
radiochemotherapy or transfusion in the Affiliated Union
Hospital of Fujian Medical University. Among the 31 GBC
patients with a median age of 63 years (range from 43 to
83 years), 17 had adenocarcinoma, 4 papillary carcinoma, 3
mucinous adenocarcinoma, 3 tubular adenocarcinoma, 2
squamous carcinoma, 1 adenosquamous carcinoma, and 1
neuroendocrine carcinoma. Sixteen patients had lymph node
metastasis (LNM), and 8 had distant metastasis. All cases
were staged clinically according to the American Joint Com-
mittee on Cancer (AJCC, 7th) [12]. The clinicopathological
characteristics of GBC patients are summarized in Table 1.
The 31 patients underwent follow-up for at least 5 months
(range 5–62 months) via telephone.
Moreover, we chose 10 patients for each of two additional
groups. One group consisted of 10 patients with cholesterol
polyps who were treated by surgery in the Affiliated Union
Hospital of Fujian Medical University. The control group in-
cluded 10 healthy volunteers. None of the cases had received
any preoperative radiochemotherapy or transfusion.
The study was approved by the institutional review board
guidelines, according to the Declaration of Helsinki.
Serum VEGF-C and VEGF-D assay with ELISA
Venous blood samples were collected according to standard
hospital procedures before surgery or anticancer therapy. We
used serum separators tubes (SST) and allowed the samples to
clot for 30 min before centrifugation for 5 min at 2000×g.
Separated serum was stored at≤−80 °C for future use.
The values of the serum VEGF-C and VEGF-D in the
collected samples were determined using the Quantikine hu-
man VEGF-C immunoassay kit (R&D Systems, Minneapolis,
USA) and the Quantikine human VEGF-D immunoassay kit
(R&D Systems, Minneapolis, USA) according to the manu-
facturers’ instructions, respectively. All samples were assayed
in duplicate, and the average was considered the serum level.
The minimum detectable dose (MDD) of VEGF-C ranged
from 4.0 to 48.4 pg/ml. The mean MDD was 13.3 pg/ml. The
MDD of VEGF-D ranged from 4.7 to 31.3 pg/ml. The mean
MDD was 11.4 pg/ml. The coefficient of variation was less
than 5.0 %.
Statistical analysis
The Shapiro-Wilk test was used to examine the normal distri-
bution of the data (VEGF-C p=0.827; VEGF-D p=0.001).
Because the sVEGF-C data had a normal distribution, all data
from the sVEGF-C groups were presented as the mean±stan-
dard deviation. The differences between these data and the
clinicopathological characteristics were evaluated using Stu-
dent’s t test for two groups and a one-way analysis of variance
(ANOVA) for more than two groups. However, the sVEGF-D
data did not have a normal distribution, and all data from the
sVEGF-D groups were characterized by the median and
range. The Mann-Whitney U test was used to assess the dif-
ferences between two groups, and the Kruskal-Wallis test was
applied to compare three or more groups. The Spearman cor-
relation coefficient test was used to determine the relationship
between sVEGF-C and sVEGF-D levels observed in the GBC
patients. Kaplan-Meier survival analysis was used to estimate
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the survival time, and the Mantel’s long-rank test was used to
compare the differences in survival time. The COX hazard
model was used to explore the independent factors of survival
and metastasis status based on the variables selected in the
univariate and multivariate analyses. We used the ROC curve
to determine the cutoff values of sVEGF-C/D for predicting
the presence of disease and LNM. The diagnostic values in-
cluded the sensitivity, specificity, accuracy, and area under the
curve (AUC). Moreover, a parallel method was applied to
further predict the presence of disease and LNM. The
Table 1 Association between sVEGF-C/D levels and clinicopathological feature of GBC
Parameters Number VEGF-C (pg/ml)a p value VEGF-D (pg/ml)b p value
Age
<63 years 15 8041.35±1925.64 0.327 703.88 (548.00–1465.13) 0.220
≥63 years 16 7321.04±2089.88 660.38 (446.50–1599.25)
Sex
Female 16 7318.29±1970.20 0.324 644.06 (461.00–1149.75) 0.105
Male 15 8044.30±2055.27 776.38 (446.50–1599.25)
Smoking status
Smoker 12 8060.85±2277.43 0.399 754.63 (446.50–1599.25) 0.543
Non-smoker 19 7422.46±1856.82 656.75 (461.00–1149.75)
Location
Neck 7 7863.53±2196.52 0.336 671.25 (548.00–1465.13) 0.082
Body 3 6775.27±734.17 569.75 (558.88–645.88)
Bottom 9 6884.40±2161.90 602.38 (446.50–921.38)
Whole 12 8368.91±1905.67 796.31 (508.13–1599.25)
Tumor size
<4 cm 14 7797.32±2166.12 0.754 627.75 (446.50–1465.13) 0.341
≥4 cm 17 7564.38±1936.99 703.88 (508.13–1599.25)
Histological type
Adeno 17 7480.00±2219.24 0.572 671.25 (446.50–1599.25) 0.451
Others 14 7899.79±1782.19 696.63 (453.75–1465.13)
Histological grading
Poor 11 8360.97±1974.50 0.378 703.88 (529.88–1465.13) 0.792
Moderate 15 7302.74±1955.52 671.25 (453.75–1599.25)
Well 5 7249.04±2278.15 689.38 (446.50–943.13)
Tumor depth
Tis-T2 10 6788.88±1945.62 0.188 544.38 (446.50–758.25) 0.001*
T3 16 7906.59±1756.33 799.94 (642.25–1465.13)
T4 5 8672.56±2618.21 678.50 (548.00–1599.25)
LNM
N0 15 6807.64±1663.66 0.011* 602.38 (453.78–823.50) 0.001*
N1 9 7725.51±2142.83 751.00 (446.50–1149.75)
N2 7 9444.69±1456.74 946.75 (678.50–1599.25)
Distant metastasis
M0 23 7177.17±1767.94 0.018* 671.25 (446.50–1073.63) 0.047*
M1 8 9085.27±2106.82 944.94 (548.00–1599.25)
Stage
0–II 9 7152.91±1663.66 0.045* 558.88 (453.75–758.25) 0.002*
III 12 6993.21±1958.07 727.44 (446.50–1073.63)
IV 10 8946.22±1913.04 944.94 (548.00–1599.25)
a Presented by mean±standard deviation
b Presented by median values and range
*p<0.05
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aforementioned statistical analyses were calculated with the
IBM SPSS Statistics 19.0, and the figures were generated in
the GraphPad Prism 5 program.
All p values were based on a two-tailed statistical analysis.
All the results were considered statistically significant at
p<0.05.
Results
The sVEGF-C/D levels in the patient group
In GBC patients, the mean sVEGF-C levels and median
sVEGF-D levels were significantly higher than the healthy
group (7669.58±2012.00 vs 4951.55±1963.48 pg/ml;
p<0.001 and 689.38 vs 502.69 pg/ml, p=0.001, respectively)
and the group with cholesterol polyps of the gallbladder
(7669.58±2012.00 vs 6134.51±1449.65 pg/ml, p=0.032
and 689.38 vs 526.25 pg/ml, p=0.004, respectively) (Figs. 1
and 2).
To evaluate the correlation between the sVEGF-C and
sVEGF-D levels, we used the Spearman Rank Correlation.
A significant and positive correlation was found between
sVEGF-C and sVEGF-D (rho=0.684, p<0.001).
Association between the clinicopathological feature
and the sVEGF-C/D levels of GBC (Table 1)
The sVEGF-C levels were associated with LNM, distant me-
tastasis, and stage (p=0.011, p=0.018 and p=0.045, respec-
tively). However, there was no association with age, sex,
smoking status, location, tumor size, histological type, or tu-
mor depth. In GBC patients, the sVEGF-C levels for patients
with LNM were significantly higher than those observed for
patients without LNM (8477.65±2018.32 vs 6807.64±
1663.66 pg/ml, p=0.018). The sVEGF-D levels had a signif-
icant association with the tumor depth, LNM, distant metas-
tasis, and stage (p=0.001, p=0.001, p=0.047, and p=0.002,
respectively), but it was not associated with age, sex, smoking
status, location, tumor size, histological type, or histological
grading. In GBC patients, there was a significant difference
between the sVEGF-D levels of patients with and without
LNM (876.06 vs 602.38 pg/ml, p=0.001).
ROC curve analysis
To further explore the diagnostic values, we used the fol-
lowing definitions: If one of the sVEGF-C/D levels was
higher than the cutoff value, it was identified as positive
in the combination (the parallel method). Moreover, all
patients underwent an examination of the CA 19-9 and
CEA before operation. Elevation of the CA 19-9 level
was defined as >37 U/ml, and elevation of the CEA level
was defined as >5 ng/ml.
When the cutoff values of sVEGF-C/D for the diagnosis of
GBC patients were 7054.83 and 595.13 pg/ml, the diagnostic
values were as follows: sensitivities of 71.0 and 74.2 %, spec-
ificities of 80.0 and 85.0 %, accuracies of 74.5 and 78.4 %,
and AUCs of 0.785 and 0.838, respectively. There was no
significant difference between sVEGF-C and sVEGF-D as
biomarkers of GBC (p=0.463) (Fig. 3). When sVEGF-C
and sVEGF-D were associated, the sensitivity was 80.6 %,
the specificity was 65.0 %, and the accuracy was 74.5 %.
The comparison with other markers is shown in Table 2.
With respect to the diagnosis of LNM, when the cutoff
values of 7667.27 and 674.88 pg/ml were selected, the diag-
nostic values of sVEGF-C /D were as follows: sensitivities of
81.2 and 87.5 %, specificities of 73.3 and 80.0 %, accuracies
of 77.4 and 83.9 %, and AUCs of 0.773 and 0.854, respec-
tively (Fig. 4). No significant difference was found between
sVEGF-C and sVEGF-D as biomarkers of LNM (p=0.28).
When we estimated the presence of LNM by combining
sVEGF-C with sVEGF-D, this method reached a sensitivity
of 87.5 %, a specificity of 60.0 %, and an accuracy of 74.2 %.
Fig. 1 The serum VEGF-C levels are presented in GBC (n=31), healthy
volunteers (n=10), and cholesterol polyp (n=10). *p<0.05
Fig. 2 The serum VEGF-D levels are presented in GBC (n=31), healthy
volunteers (n=10), and cholesterol polyp (n=10). *p<0.05
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Prognosis analysis
In 31 patients, the median survival time was 19 months, and
the median follow-up time was 24 months. The follow-up rate
reached 93.5 %. The 1-year survival rate was 63.8 %. The
mean survival time of patients with a high sVEGF-C level
(>7669.58 pg/ml) was 10.70 months (n=17, 95 % confidence
interval (CI) 5.23–16.17), while the low sVEGF-C level
(<7669.58 pg/ml) was 52.26 months (n=14, 95 % CI 39.86–
64.65) (p<0.001). The high sVEGF-D group (>689.38 pg/ml)
had a mean survival time of 22.16 months (n=15, 95 % CI
8.23–36.09), but the low sVEGF-D group (<689.38 pg/ml)
had a mean survival time of 44.84 months (n=16.95 % CI
30.39–59.29) (p=0.032) (Figs. 5 and 6).
We performed univariate analysis for the clinicopatho-
logical factors and sVEGF-C/D levels that might affect
survival and further performed multivariate analysis using
the variables that were significant in the univariate analy-
sis. The overall survival rates of GBC patients were inde-
pendently associated with the TNM stage (p=0.013) and
sVEGF-C level (p=0.018) (Table 3).
Discussion
We demonstrated that the sVEGF-C and sVEGF-D levels
were significantly higher in GBC patients than in healthy peo-
ple and patients with cholesterol polyps of the gallbladder.
Additionally, the sVEGF-C and sVEGF-D levels in GBC pa-
tients had a significant, positive correlation. These findings
suggested that the sVEGF-C and sVEGF-D levels were lower
in the noncancerous gallbladder when transitioning into can-
cerous cells, and the tumor cells would secrete high levels of
VEGF C/D, thereby inducing the growth of tumor lymphatic
vessels. Our finding was in accordance with the studies of
lung cancer [13] and esophageal cancer [14]. These studies
reported that the sVEGF-C and sVEGF-D levels in the pa-
tients with carcinoma were significantly higher than the levels
observed in healthy people or those with benign disease.
However, several studies in gastric cancer patients have
reported conflicting results. Tsirlis et al. [15] from Greece
observed that the preoperative sVEGF-C level was signif-
icantly lower than that observed in controls but that the
preoperative sVEGF-D level was significantly higher than
that in controls. In contrast, Al-Moundhri et al. [16] from
Oman demonstrated that there were no significant
Fig. 3 ROC curve analysis for predicting the presence of GBC by serum
VEGF-C and VEGF-D (cut-off values 7054.83 and 595.13 pg/ml,
respectively)
Fig. 4 ROC curve analysis for the prediction of LNMby serumVEGF-C
and VEGF-D (cut-off values 7667.27 and 674.88 pg/ml, respectively)
Fig. 5 Kaplan-Meier survival curves in the low sVEGF-C (<7669.58 pg/
ml) and high sVEGF-C groups (>7669.58 pg/ml). *p<0.05
Table 2 Comparison of VEGF-C/D, CEA, and CA19-9 in predicting
the presence of GBC
Parameters Sensitivity Specificity PPVa NPVb Accuracy
VEGF-C 71.0 % 80.0 % 84.6 % 64.0 % 74.5 %
VEGF-D 74.2 % 85.0 % 88.5 % 68.0 % 78.4 %
VEGF-C+D 80.6 % 65.0 % 78.1 % 68.4 % 74.5 %
CEA 41.9 % 95.0 % 92.9 % 51.4 % 62.8 %
CA19-9 54.8 % 90.0 % 89.5 % 56.3 % 68.6 %
CEA+CA19-9 64.5 % 85.0 % 87.0 % 60.7 % 74.0 %
a Positive predictive value
bNegative predictive value
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differences in the serum VEGF-C levels between gastric
adenocarcinoma patients and controls, whereas the serum
levels of VEGF-D were significantly higher in control sub-
jects than in gastric adenocarcinoma patients. These results
suggested that different cancers and areas might lead to
different sVEGF-C and sVEGF-D expression. VEGF-C
and VEGF-D can both combine with VEGFR-2 and
VEGFR-3, and they might compete with each other [17].
Therefore, the expression depends on respective binding to
receptors, which may be influenced by many factors in the
cohort of patients, such as the tumor type, area, and ad-
vanced tumor stage presentation [16]. There seemed to be
no significant differences in the binding between VEGF-C
and VEGF-D in our study. In contrast, VEGF-C and
VEGF-D cooperate in the occurrence and progression of
GBC. More studies are required to validate these
assertions.
This study has analyzed the associations between the clin-
icopathological characteristics and the sVEGF-C/D levels in
GBC. We found that the levels of sVEGF-C were related to
the LNM, distant metastasis, and clinical stage. Additionally,
there were significant correlations between the levels of
sVEGF-D and tumor depth, LNM, distant metastasis, and
clinical stage. We demonstrated that sVEGF-C/D was upreg-
ulated in advanced GBC. The sVEGF-C/D levels in patients
with LNM were significantly higher than those in patients
without LNM. A gradual increasing trend was observed in
the levels of sVEGF-C/D from N0 to N2. Tumor cells could
increase the secretion of VEGF-C/D, which could induce lym-
phatic vascular growth and increase the risk of metastasis. Our
observations were consistent with those of some other studies.
Nakashima et al. [18] suggested that VEGF-C expression was
significantly correlated with lymph node metastasis in GBC
patients. A study on papillary thyroid carcinoma [11] found
that the serum VEGF-D levels in patients with LNM were
significantly higher than in those without metastases. Addi-
tionally, VEGF-D overexpression has previously been ob-
served in gastric cancer patients with distant metastasis [19].
Moreover, another study on esophageal cancer [14] reported
that the upregulation of the sVEGF-C levels correlated with
LNM, the stage, and distant metastases and that elevated
levels of sVEGF-D were associated with the tumor depth,
stage, and LNM. However, the sVEGF-C levels do not corre-
late with LNM in the cervical squamous cell carcinoma [20].
Some studies [14, 20] have reported that VEGF-C overexpres-
sion has a significant correlation with tumor size, but we did
not find an association between them. It seems that there is no
association between the tumor size and stage but that the stage
is associated with the VEGF-C/D levels. Therefore, we in-
ferred that there is no significant correlation between the tu-
mor size and VEGF-C/D levels.
Fig. 6 Kaplan-Meier survival curves in the low sVEGF-D (<689.38 pg/
ml) and high sVEGF-D groups (>689.38 pg/ml). *p<0.05
Table 3 Results of COX’s univariate and multivariate analysis
Factors Univariate analysis Multivariate analysis
Odd ratio 95 % CI p value Odd ratio 95 % CI p value
Age 0.976 0.918–1.037 0.432
Sex (male/female) 0.531 0.182–1.548 0.246
Smoking Status (smoker/non-smoker) 0.463 0.161–0.337 0.155
Tumor location (neck/body/bottom/whole) 0.864 0.528–1.414 0.561
Tumor size (cm) 1.370 0.470–3.992 0.564
Histological type (adeno/others) 1.045 0.583–1.874 0.882
Histological grading (poor/moderate/well differentiation) 0.498 0.210–1.182 0.114
Tumor depth (Tis-T2/T3/T4) 4.203 1.837–9.616 0.001* 0.349 0.053–2.294 0.273
LNM (N0/N1/N2) 4.051 1.83–8.965 0.001* 0.277 0.044–1.725 0.169
Distant metastasis (M0/M1) 8.795 2.754–28.087 <0.001* 1.548 0.214–11.219 0.665
Stage (0–II/III/IV) 6.844 2.408–19.449 <0.001* 68.659 2.466–1191.634 0.013*
sVEGF-C (pg/ml) 0.122 0.027–0.551 0.006* 0.006 0–0.412 0.018*
sVEGF-D (pg/ml) 0.312 0.098–0.998 0.05* 2.171 0.38–12.413 0.384
*p<0.05
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It has been suggested that the serum VEGF-C/D might
predict the presence of malignancy. Previous results [14] have
demonstrated that the diagnostic values of the serum VEGF-
C/D levels, when used as markers of esophageal cancer, were
as follows: sensitivities of 60 and 52 % and specificities of 80
and 78 %. In our study, when the sVEGF-C/D levels reached
the cutoff values of 7054.83 and 595.13 pg/ml, the diagnosis
values for the presence of malignancy were sensitivities of 71
and 74.2 % and specificities of 80.0 and 85.0 %, but no sig-
nificant difference was found between sVEGF-C and sVEGF-
D when they were used as biomarkers of GBC. At present,
other markers such as the serum CA242, CEA, and CA 19-9
levels are often used to predict the presence of GBC in clinical
practice [21, 22]. This study compares the differences in the
VEGF-C/D, CEA, and CA 19-9 serum levels, both indepen-
dently and in combination, as diagnostic markers for GBC.
We found that the sensitivities of the serum CEA and CA 19-9
levels are too low, which can more easily result in misdiagno-
sis. According to our study, the serum VEGF-C/D levels may
be more promising tumor markers for GBC than CEA and CA
19-9, particularly in terms of sensitivity.
It has been confirmed that the circulating VEGF-C/D levels
can distinguish between the presence and absence of LNM in
various malignancies. In the gastric cancer, the level of
SVEGF-C reached the highest sensitivity (82.8 %) and spec-
ificity (81.8 %) for diagnosing LNM when a cutoff value of
542.5 ng/L was used [10]. Additionally, in colorectal cancer,
the predicted LNM sensitivity and specificity of SVEGF-C
were 85.7 and 80.0 %, respectively (875 pg/ml cutoff) [23].
When using the cutoff point of 215.04 pg/ml in papillary
thyroid carcinoma, the corresponding sensitivity and specific-
ity for serum VEGF-D were 69.6 and 62.7 %, respectively
[11]. The diagnostic values of sVEGF-C and sVEGF-D as
lymph node markers in esophageal cancer were as follows:
sensitivities of 74 and 58 % and specificities of 61 and 50 %
[14]. In our study, when the cutoff values of the sVEGF-C/D
levels as the markers of LNM were 7667.27 and 674.88 pg/
ml, respectively, the predicted values were as follows: sensi-
tivities of 81.2 and 87.5 % and specificities of 73.3 and 80 %.
Therefore, we suggested that the serum VEGF-C/D levels
might be the reliable biomarkers for LNM in GBC.
To further evaluate the values, we predicted the presence of
disease and LNM using a combination of the sVEGF-C and
sVEGF-D levels. Through this test, the sensitivity was higher
than single-marker assays, but lower accuracy was obtained. It
is generally known that improving the sensitivity can reduce
the rate of missed diagnosis, which is of great importance for
GBC, whose diagnosis is often missed. Our findings were in
agreement with the study on non-small cell lung cancer [24],
which showed that by using the combination of high sVEGF
and sVEGF-C levels, 84.2 % of the cases had positive lymph
nodes, which was a significantly higher rate than found when
using single-marker assays.
In this study, we observed that the mean survival time with
high sVEGF-C was significantly shorter than that observed
with low sVEGF-C, as well as high sVEGF-D. The COX
analysis showed that the sVEGF-C level might be an indepen-
dent risk factor of the outcome for GBC. These findings were
consistent with those reports showing that a high sVEGF-C
level was related to poor prognosis in patients with breast
tumors [25] and gastric cancer [10]. Other studies have report-
ed that overexpression of VEGF-C was correlated with a poor
outcome in GBC patients [18] and that the serum VEGF-D
level in PTC patients might be a useful marker for predicting
the outcome [11]. These studies suggested that sVEGF-C/D
could be useful in predicting the prognosis of GBC patients,
which could be because high sVEGF-C/D levels in GBC pa-
tients increase the risk of LNM, distant metastasis, and ad-
vanced stage, thereby decreasing the chance of radical resec-
tion and resulting in poor outcomes. However, colorectal can-
cer patients with low sVEGF-C levels showed a poorer overall
survival than did those with high sVEGF-C levels [26]. In
esophageal cancer, there is a significant correlation between
the pretreatment serum levels of VEGF-C and survival in
patients undergoing surgery, instead of serum VEGF-D [14].
Therefore, further experiments are required to rigorously test
these conjectures.
To the best of our knowledge, our study is the first to
describe the serum VEGF-C/D levels in patients with GBC
and their values in the diagnosis and prognosis. However, the
study has some limitations that require further discussion.
First, because of the small sample size of GBC patients, which
resulted in wide confidence intervals in our analysis, the find-
ings could easily be spurious; thus, larger sample sizes will be
needed in future studies. Second, the postoperative serum
VEGF-C/D levels should be measured and compared with
the preoperative levels to compare the diagnosis with
sVEGF-C/D. Another limitation was the possibility of selec-
tion bias because not all GBC patients could provide serum for
the analysis, and we finally settled on a sample size of 31GBC
patients.
In conclusion, our work suggested that the sVEGF-C/D
levels could be used as reliable biomarkers for predicting the
metastasis status and prognosis of GBC patients, thus enabling
preparation for and selection of the best treatment in advance.
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